Humanin: What the Research Actually Shows About This Mitochondrial Peptide

What Is Humanin and Where Does It Come From?

Humanin is a short peptide whose gene sits inside the mitochondrial genome, not the nuclear genome, which makes it unusual among signaling molecules. Researchers at the University of Tokyo identified it in 2001 while screening a cDNA library derived from the surviving neurons of an Alzheimer's disease patient. The original paper, published in the Proceedings of the National Academy of Sciences, showed that humanin blocked cell death caused by familial Alzheimer's disease gene products including APP, presenilin-1, and presenilin-2 mutations. [1]

The peptide is 21 amino acids long in its natural form. A synthetic analog called HNG (Ser14Gly humanin) substitutes glycine for serine at position 14 and is roughly 1,000-fold more potent in cell-based neuroprotection assays. [2] Most laboratory studies now use HNG rather than native humanin because of this potency advantage.

Humanin signals through at least two receptor systems. The first is an intracellular pathway involving STAT3 phosphorylation. The second is a cell-surface tripartite receptor made up of ciliary neurotrophic factor receptor alpha (CNTFR-alpha), glycoprotein 130 (GP130), and leukemia inhibitory factor receptor beta (LIFR-beta). [3] Activation of this complex triggers JAK-STAT and MAPK cascades that suppress apoptosis and reduce inflammatory cytokine output.

Circulating humanin declines with age in humans. A cross-sectional analysis published in Aging (2013) measured serum humanin in adults across a wide age range and found a significant inverse correlation between age and humanin concentration. [4] That single observation became foundational to the argument that humanin replacement could theoretically slow age-associated decline, though no randomized trial has tested that hypothesis directly in humans.

How Humanin Works at the Cellular Level

The core mechanism is anti-apoptotic. Humanin binds BAX, a pro-apoptotic protein in the BCL-2 family, and prevents it from translocating to the mitochondrial outer membrane. [5] When BAX cannot reach the mitochondria, cytochrome c stays inside the organelle, the caspase cascade does not fire, and the cell survives a signal that would otherwise kill it.

A secondary mechanism involves insulin signaling. Humanin activates the insulin-like growth factor 1 receptor (IGF-1R) and its downstream substrate IRS-1, which improves glucose uptake in skeletal muscle cells in culture. [6] This observation connects humanin to the broader metabolic longevity literature because centenarians frequently show preserved insulin sensitivity.

Inflammatory modulation is a third pathway. Humanin suppresses NF-kB activation and reduces output of IL-6, TNF-alpha, and IL-1-beta in macrophage cell lines. [7] Lower chronic low-grade inflammation is associated with slower biological aging in multiple epidemiological datasets, so this pathway draws considerable research interest even though human intervention data remain limited.

The three pathways, anti-apoptotic, metabolic, and anti-inflammatory, do not operate in isolation. A 2019 review in Nature Reviews Drug Discovery described mitochondrial-derived peptides (MDPs) as a new class of signaling molecules that coordinate cellular stress responses across tissues simultaneously. [8] Humanin is the best-characterized member of that class, but MOTS-c, SHLP2, SHLP3, and SHLP6 are now recognized as co-members of the same mitochondrial signaling network.

Humanin and Neuroprotection: What the Data Show

Cell-culture and animal data are the strongest body of evidence for humanin's neuroprotective effects. In mouse models of Alzheimer's disease, intracerebroventricular injection of HNG reduced amyloid plaque burden and improved performance on Morris water maze spatial memory tests compared with saline controls. [9] The effect size in these models is reproducible across at least four independent laboratories, which adds confidence even though animal-to-human translation remains uncertain.

Human observational data are more limited but suggestive. Nir Barzilai's longevity cohort at Albert Einstein College of Medicine measured serum humanin in Ashkenazi Jewish centenarians, their offspring, and age-matched controls without centenarian parents. Offspring of centenarians had statistically higher humanin levels than controls (P<0.05), suggesting a heritable component to humanin production. [10]

A separate analysis from the USC Davis School of Gerontology found that individuals with insulin-dependent diabetes mellitus had lower circulating humanin than age-matched non-diabetic subjects. [11] This finding is consistent with the IGF-1R signaling mechanism described above and raises the question of whether humanin deficiency contributes to diabetic neurodegeneration, though causality has not been established.

No Phase II or Phase III randomized controlled trial of humanin for any neurological condition has been completed and published as of early 2025.

Humanin, Cardiovascular Risk, and Metabolic Health

Animal studies show that humanin reduces atherosclerotic plaque formation. In apolipoprotein E-knockout mice fed a high-fat diet, subcutaneous HNG infusion for 12 weeks decreased aortic plaque area by approximately 30% compared with vehicle-injected controls. [12] The mechanism appeared to involve reduced macrophage infiltration into plaque rather than changes in LDL cholesterol levels.

In humans, a small pilot study (N=28) published in Endocrinology measured humanin levels in subjects with and without metabolic syndrome. Those with metabolic syndrome had mean humanin concentrations about 40% lower than healthy controls, even after adjusting for age and BMI. [13] The study was cross-sectional, so direction of causality cannot be determined.

Humanin also shows protective effects on pancreatic beta cells in diabetic mouse models. Administration of HNG to streptozotocin-treated mice preserved beta-cell mass and improved fasting glucose compared with untreated diabetic controls. [14] This beta-cell protective effect is one reason some longevity-focused clinicians have speculated about humanin as an adjunct in type 2 diabetes care, though clinical trial data do not yet support prescribing it for that indication.

Epitalon: A Pineal Peptide With Different Targets

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its proposed mechanism centers on telomere biology: epitalon reportedly stimulates telomerase activity, the enzyme that adds protective repeats to chromosome ends. [15]

Preclinical data in rats and mice show that epitalon treatment extended median lifespan by 13-24% in some studies and reduced tumor incidence in cancer-prone strains. [16] A human observational study of 266 elderly patients at a St. Petersburg clinic reported reduced mortality over 6 years in the group receiving peptide bioregulator treatment that included epitalon, compared with an untreated comparison group. [17] That study was not a blinded RCT, and the comparison group was not perfectly matched, so the result should be interpreted with caution.

Epitalon differs from humanin in both target tissue and mechanism. Humanin acts primarily in the nervous system, vasculature, and metabolic tissues via the JAK-STAT and BAX pathways. Epitalon's proposed target is the pineal gland and the telomere maintenance machinery. Whether they have additive effects when combined has not been tested in any published study.

MOTS-c: The Mitochondrial Peptide That Mimics Exercise

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide also encoded in the mitochondrial genome. A landmark 2015 paper in Cell Metabolism by Lee et al. showed that MOTS-c regulates glucose metabolism in skeletal muscle by activating the AMPK pathway and suppressing the folate cycle, leading to an increase in AICAR, a natural AMPK activator. [18] Mice injected with MOTS-c showed improved insulin sensitivity, reduced weight gain on a high-fat diet, and enhanced exercise performance compared with controls.

MOTS-c circulating levels, like humanin, decline with age and with obesity. A 2023 study in Nature Aging (N=141) found that MOTS-c concentrations were significantly lower in older sedentary adults than in younger adults or older adults who exercised regularly (P<0.001). [19] This has prompted the hypothesis that some of the metabolic benefits of exercise are mediated through increased MOTS-c secretion from contracting muscle mitochondria.

MOTS-c and humanin share mitochondrial origin but have distinct receptors and tissue targets. Humanin acts mostly through the CNTFR-alpha / GP130 / LIFR complex in neurons and vascular cells. MOTS-c acts through AMPK in skeletal muscle and adipose tissue. Combining them theoretically covers more metabolic pathways, but no clinical trial has tested co-administration.

SS-31: Targeting Mitochondrial Inner Membrane Cardiolipin

SS-31 (elamipretide, also called MTP-131 or Bendavia) is a tetrapeptide that targets cardiolipin, a phospholipid embedded in the mitochondrial inner membrane. Cardiolipin maintains the architecture of the electron transport chain; its oxidation during ischemia-reperfusion injury disrupts ATP production and triggers apoptosis. SS-31 binds cardiolipin and reduces its oxidation. [20]

Unlike humanin and MOTS-c, SS-31 has reached human clinical trials. The PROGRESS-HF trial tested elamipretide in 71 patients with heart failure with reduced ejection fraction (HFrEF) over 4 weeks. The trial did not meet its primary endpoint of improved left ventricular end-systolic volume, though a pre-specified subgroup with a lower baseline ejection fraction showed a trend toward improvement. [21] A separate trial in Barth syndrome, a rare mitochondrial cardiomyopathy, showed significant improvement in the 6-minute walk test with SS-31 vs. placebo. [22]

SS-31 remains an investigational drug in the United States. It is not FDA-approved for any indication as of early 2025.

FOXO4-DRI: A Senolytic Peptide Targeting Zombie Cells

FOXO4-DRI is a D-amino acid retro-inverso peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53 inside senescent cells. Senescent cells, sometimes called "zombie cells," accumulate with age and secrete a cocktail of inflammatory mediators called the senescence-associated secretory phenotype (SASP). [23]

A 2017 paper in Cell by Baar et al. showed that FOXO4-DRI injection in naturally aged mice and in mice with chemotherapy-induced senescence selectively killed senescent cells without harming non-senescent cells. Treated mice showed improved fur density, improved renal function, and increased physical activity compared with vehicle-injected controls. [24] The paper attracted enormous attention because it demonstrated that a peptide could act as a senolytic with apparent tissue selectivity.

FOXO4-DRI differs fundamentally from humanin. Humanin is cytoprotective; it keeps cells alive under stress. FOXO4-DRI is senolytic; it kills specific cells. The two could theoretically be used in complementary fashion, protecting healthy cells while clearing senescent ones, but this combination has not been studied in any published trial, animal or human.

No clinical trial of FOXO4-DRI in humans has been completed as of early 2025.

Dosing: What the Published Research Used

No FDA-approved dosing guideline exists for humanin, MOTS-c, or FOXO4-DRI. Elamipretide (SS-31) has the most structured human dosing data from its clinical trial program.

For humanin specifically, the published animal studies most commonly used intraperitoneal or subcutaneous injections of native humanin or HNG at doses ranging from 2 mcg/kg to 8 mg/kg depending on the endpoint and species. [9][12] These doses do not translate directly to human equivalents without formal pharmacokinetic bridging studies, which have not been published.

The Yen et al. human observational work measured endogenous humanin rather than administering exogenous peptide, so it provides no dosing information. Some compounding pharmacies offered subcutaneous humanin at doses of 100-500 mcg per injection before the 2024 FDA actions, but those doses were not derived from controlled clinical trials.

The 2024 FDA actions on compounded peptides removed several mitochondrial peptides from permitted compounding lists under the Federal Food, Drug, and Cosmetic Act's provisions on bulk drug substances. [25] Patients who were receiving compounded humanin, MOTS-c, or epitalon through 503A compounding pharmacies should consult their prescribing physician about alternative protocols, since availability varies by state and pharmacy accreditation status.

Safety Profile and Known Risks

Published safety data for humanin in humans are sparse. The peptide's short half-life (estimated 2-4 hours in rodent models) suggests it would not accumulate with intermittent dosing, but human pharmacokinetic studies have not been published. [8]

Cell culture data show that very high humanin concentrations can paradoxically promote survival of cancer cells that rely on anti-apoptotic signaling for persistence. [26] This theoretical oncological risk is one reason oncologists generally advise against peptide supplementation in patients with active malignancy, though no human clinical report has documented tumor promotion from exogenous humanin.

MOTS-c has a similar sparse human safety record. SS-31 in its trial program was generally well tolerated; the most common adverse events in the PROGRESS-HF trial were injection-site reactions reported in about 12% of participants. [21]

FOXO4-DRI carries a theoretical risk of off-target senescent cell clearance in tissues where some degree of senescence serves protective functions, such as wound healing. This has not been reported as a clinical problem in the mouse studies, but human data are absent.

Regulatory Status in 2025

The FDA does not recognize humanin, MOTS-c, epitalon, or FOXO4-DRI as approved drugs. Elamipretide (SS-31) holds Orphan Drug designation for Barth syndrome but is not approved. [27]

In 2024, the FDA updated its list of bulk drug substances that may not be used in compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Several peptides used in longevity and performance protocols were added to the Category 2 list, which signals that the agency does not believe adequate evidence of clinical benefit exists to justify their compounded use. [25]

Patients seeking these peptides outside a clinical trial setting should be aware that offshore or unregulated sources carry significant risks: contamination with endotoxins, incorrect concentration, and lack of sterility testing. A 2022 FDA warning letter to a peptide distributor documented product contamination and mislabeling across multiple peptide compounds. [28]

The American Association of Clinical Endocrinologists has not issued specific guidance on mitochondrial peptides as of early 2025, and no major endocrinology society guideline endorses humanin supplementation for any clinical indication. [29]